Targepeutics Secures $200K Seed Funding to Accelerate Precision Oncology Breakthroughs

Targepeutics is proud to announce that we have successfully raised $200,000 in our latest funding round—a pivotal step forward in our mission to redefine cancer treatment and diagnosis through groundbreaking molecularly targeted therapeutics. As a biopharmaceutical company dedicated to developing innovative solutions, our focus remains on fighting cancer and other life-threatening diseases with precision and care. This crucial investment will accelerate the development and clinical progression of our lead compound, GB-13, a genetically engineered recombinant protein designed to selectively bind and destroy cancer cells while minimizing damage to healthy tissue. GB-13, which is now advancing toward a Phase I clinical trial, stands as a beacon of hope for patients and clinicians alike, offering a more targeted approach to cancer treatment that could reduce side effects and improve outcomes. In addition to our flagship program, the funding will bolster efforts to further license and advance our related technology in cancer immunotherapy, which is currently undergoing Phase III clinical trials. The infusion of capital underscores investor confidence in Targepeutics’ innovative approach and our steadfast commitment to transforming the therapeutic landscape. With these funds, we are positioned to expand our research capabilities, streamline clinical trial processes, and take critical steps toward regulatory approvals. At Targepeutics, every advancement brings us closer to a future where cancer is met with precision, safety, and relentless innovation—a future where patients can look forward to more effective and personalized treatment options. We thank our investors and partners for their unwavering support as we continue our journey to combat cancer with targeted precision and groundbreaking science.